Evaluation of Intraoperative Dexmedetomidine Use in Patients Undergoing Surgical Aortic Valve Replacement

Evaluation of Intraoperative Dexmedetomidine Use on Reducing Inflammatory Response Caused by Cardiopulmonary Bypass in Patients Undergoing Surgical Aortic Valve Replacement

Aim of this randomized prospective study is to investigate the immunomodulatory effects of dexmedetomidine on outcomes in patients with isolated aortic stenosis after surgical aortic valve replacement.

Study will investigate effects of two different doses of dexmedetomidine on concentrations of tumor necrosis factor-α and interleukin-6, on inflammatory parameters (C reactive protein and procalcitonin) and inflammatory complications, renal function, postoperative delirium, anaesthetic and analgetic consumption and compare it to control group. It should provide a better understanding of dexmedetomidine effect on decrease of inflammatory response in patients undergoing cardiac surgery. Short-term infusion of dexmedetomidine could reduce inflammatory postoperative complications, contribute to improvement of perioperative renal function and occurrence of postoperative delirium, supporting recovery and shortening hospital stay.

Inclusion Criteria:

• isolated aortic stenosis adult patients with written consent

Exclusion Criteria:

• BMI <30kg/m2
• 1st, 2nd and 3rd degree AV block
• bradycardia HR<50/min upon arrival to operating theatre
• neurological disorders (Parkinson's disease, Myasthenia gravis, multiple sclerosis, brain tumors in anamnesis)
• recent use of psychoactive drugs
• alcohol and illicit drug addiction
• diabetes type I with complications
• patients who develop hypotension after initiation of dexmedetomidine infusion requiring vasoconstriction therapy
• patients receiving corticosteroids in perioperative period
• patients with known allergy to dexmedetomidine